An interventional study of Microport NeuroTech Tubridge Plus flow-diverter Stent in Intracranial Aneurysm, sponsored by MicroPort NeuroTech Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-12.
Sponsored by MicroPort NeuroTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.
Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 37th largest by planned enrollment of the 49 interventional ones that give a count, is one of 20 that started in 2023, is one of 37 with no phase, reaches primary completion later than 4 of the 41 other live ones, and was the 58th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Henan Provincial People's Hospital · Sites in China
Ages 18–75
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–75
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 22–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 9
First in 2005; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99 is close to the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.
Median enrollment 188 across the 49 interventional studies, 600 across the 51 observational. Of the 27 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 100 have an industry lead sponsor. The 10 most frequent:
This study is registered under MicroPort NeuroTech Co., Ltd., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort NeuroTech Co., Ltd. is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
MicroPort Scientific Corporation has 8 studies filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
7 of the studies in Intracranial Aneurysm with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06943729Huashan HospitalClinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms | 2026-12-30 |
| NCT06364293Beijing Tiantan HospitalAn Early Warning Model of Unfavorable Outcomes Following Endovascular Interventional Treatment of Intracranial Aneurysm | 2026-12-31 |
| NCT07089862Beijing Tiantan HospitalINdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) | 2026-12-31 |
| NCT07674004Henan Provincial People's HospitalSurface-Modified Flow Diverter for Intracranial Aneurysms: Assessment of Ischemic and Clinical Outcomes | 2027-02-28 |
| NCT07707076Nanfang Hospital, Southern Medical UniversityFlow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 100 studies in Intracranial Aneurysm with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A trial to evaluate the safety and efficacy of the Tubridge Plus flow-diverter stent for the treatment of intracranial wide-necked aneurysms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Microport NeuroTech Tubridge Plus flow-diverter Stent
Intracranial stent for wide-necked aneurysms
Complete occlusion(Raymond I) rate of aneurysm at 6 months after procedures
Complete occlusion(Raymond I) rate of aneurysm at 6 months after procedures
Time frame: 6months±30 days
Complete occlusion(Raymond I) rate of aneurysm at 12 months after procedures
Complete occlusion(Raymond I) rate of aneurysm at 12 months after procedures
Time frame: 12months±60 days
Successful treatment(Raymond I or II)rate of aneurysm at 6 months after procedures
uccessful treatment(Raymond I or II)rate of aneurysm at 6 months after procedures
Time frame: 6months±30 days
Successful treatment(Raymond I or II)rate of aneurysm at 12 months after procedures
Successful treatment(Raymond I or II)rate of aneurysm at 12 months after procedures
Time frame: 12months±60 days
Retreatment rate of target aneurysm during follow-up
Retreatment rate of target aneurysm during follow-up
Time frame: 12months±60 days
Success rate of stent implantation
Success rate of stent implantation
Time frame: Immediate evaluation after intervention
The proportion of subjects with ipsilateral stroke or neurogenic death to their target aneurysm at 1 month postoperatively, 6 months postoperatively, and 1 year postoperatively;
The proportion of subjects with ipsilateral stroke or neurogenic death to their target aneurysm at 1 month postoperatively, 6 months postoperatively, and 1 year postoperatively;
Time frame: 12months±60 days
The proportion of subjects with in-stent stenosis (stenosis ≥50% and <100%) within 6 months after procedures
The proportion of subjects with in-stent stenosis (stenosis ≥50% and \<100%) within 6 months after procedures
Time frame: 6months±30 days
Proportion of subjects with complete in-stent occlusion within 6 months after procedures
Proportion of subjects with complete in-stent occlusion within 6 months after procedures
Time frame: 6months±30 days
Device-related adverse events, serious adverse events within 1 month, 6 months, and 1 year after procedures
Device-related adverse events, serious adverse events within 1 month, 6 months, and 1 year after procedures
Time frame: 12months±60 days
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Mar 2024, 10 months after the start.
Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 10 months is below that.
Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MicroPort NeuroTech Co., Ltd. →